{"id":"NCT01725529","sponsor":"Janssen R&D Ireland","briefTitle":"An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of TMC435 vs. Placebo as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve, Genotype 1 Hepatitis C-Infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11","primaryCompletion":"2014-08","completion":"2014-11","firstPosted":"2012-11-14","resultsPosted":"2015-08-13","lastUpdate":"2015-08-13"},"enrollment":457,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"TMC435","otherNames":[]},{"type":"DRUG","name":"Peginterferon-alpha (PegIFNα-2a)","otherNames":[]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TMC435 150 mg","type":"EXPERIMENTAL"},{"label":"TMC435 100 mg","type":"EXPERIMENTAL"},{"label":"Control","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to provide confirmatory efficacy and safety data of TMC435 as part of a treatment regimen including peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) in patients with genotype 1 Hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)","timeFrame":"12 weeks after the end of treatment (EOT: Week 24 or 48)","effectByArm":[{"arm":"Placebo","deltaMin":75.7,"sd":null},{"arm":"Simeprevir (TMC435) 100mg","deltaMin":88.9,"sd":null},{"arm":"Simeprevir (TMC435) 150mg","deltaMin":90.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":21,"countries":["China","South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":152},"commonTop":["Neutrophil count decreased","White blood cell count decreased","Platelet count decreased","Haemoglobin decreased","Anaemia"]}}